Welcome to www.myelofibrosisinsights.be

For healthcare professionals - information on Myelofibrosis, symptoms, disease-related educational resources and more.

Important notice: this site is intended for healthcare professionals. By entering this site, you are confirming that you are a healthcare professional.

This site is intended for members of the Belgium and the Grand Duchy of Luxembourg public, patients and their carers.

May 2026 - NP-BE-MML-WCNT-260001

CONTACT

GlaxoSmithKline Pharmaceuticals s.a./n.v.
Avenue Fleming 20
1300 Wavre Belgium

Report a possible side effect

Belgium 
Please report adverse events to the Belgian Centre for Pharmacovigilance for medicines for Human use of the Federal Agency for Medicines and Health Products via adr@afmps.be or via www.notifieruneffetindesirable.be or to GlaxoSmithKline Pharmaceuticals s.a./n.v. via be.medinfo@gsk.com.

Grand Duchy of Luxembourg 
Please report adverse events to the Centre Régional de Pharmacovigilance de Nancy or Division de la pharmacie et des médicaments de la Direction de la santé via www.guichet.lu/pharmacovigilance or to GlaxoSmithKline Pharmaceuticals s.a./n.v. via be.medinfo@gsk.com